Bone Marrow Transplant in Treating Patients With Hematologic Cancers

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

PURPOSE: This phase II trial is studying how well donor bone marrow transplant works in treating patients with hematologic cancers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
• Collaborator: National Cancer Institute (NCI)
• Treatments: Busulfan; Cyclophosphamide; Etoposide; Etoposide phosphate

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of:

• Acute myelogenous leukemia

• Complete remission (CR) 1 - ALL except good cytogenetics defined as [(inv16, t(8,21), t(15,17)]

• CR2

• Induction failures

• Relapsed OR

• Acute lymphocytic leukemia (ALL)

• CR1 - high risk defined as overt CNS involvement, 1 or more risk factors (age 30 and over, WBC at least 20,000/mm^3, at least 4 weeks to CR1, myeloid phenotype)

• CR2

• Induction failures

• Relapsed OR

• Chronic myelogenous leukemia

• Chronic phase (CP) 1

• Accelerated phase (AP)/CP2 OR

• Chronic lymphocytic leukemia

• At diagnosis - RAI stage III/IV or Binet C

• Must undergo 1 induction regimen

• Relapsed - any stage

• Must have received no more than 3 regimens for diagnosis OR

• Multiple myeloma

• At diagnosis - stage II/III (primary refractory or sensitive)

• Relapsed no more than 2 times - sensitive disease

• Plasma cell leukemia OR

• Myelodysplasia

• All subtypes eligible OR

• Myeloproliferative disorders

• Poor response to medical therapy OR

• Cytogenetic abnormalities

• Must have a related donor who is genotypic 6 out of 6 HLA A, B, and DR match

• Molecular DR matching required

PATIENT CHARACTERISTICS:

Age:

• 15 to 55

Performance status:

• Karnofsky 80-100%

Life expectancy:

• Not specified

Hematopoietic:

• See Disease Characteristics

Hepatic:

• Bilirubin no greater than 2.0 mg/dL

• SGOT/SGPT no greater than 3 times upper limit of normal

• PT/PTT normal

Renal:

• Creatinine no greater than 2.0 mg/dL

• Creatinine clearance at least 60 mL/min

Cardiovascular:

• LVEF at least 45% by MUGA scan or echocardiography

• No myocardial infarction within the past 6 months

• No arrhythmias controlled by therapy

Pulmonary:

• FEV_1 at least 50% predicted

• DLCO at least 50% predicted

Other:

• Not pregnant or nursing

• Negative pregnancy test

• No diabetes mellitus or thyroid disease that is not medically controlled

• No psychosocial disorder that would preclude study compliance

• No active serious infections

• HIV negative

• Donor must be HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• See Disease Characteristics

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified